Intendis GmbH, which is part of Bayer HealthCare, has signed an agreement to acquire two prescription dermatology product lines from SkinMedica, Inc., a dermatology company based in Carlsbad, CA, USA. Both Desonate® and NeoBenz® Micro are currently marketed in the U.S. by SkinMedica, Inc. Under the transaction, which is still subject to the necessary regulatory approvals, Intendis will acquire all commercial rights, including assigned contracts and intellectual property related to the two product lines. The deal is expected to close in the Fall of 2009.
"We are currently seeing solid growth of our existing portfolio of prescription dermatologicals in the U.S. With the addition of these two high-quality product lines we expect to build on this dynamic and to substantially strengthen our presence in this key strategic business," stated Marc Lafeuille, President and CEO of the Intendis Group. In 2008, the company grew by 18.7% on a currency-adjusted basis in the U.S.
Desonate® is a low potency topical corticosteroid for the treatment of mild to moderate atopic dermatitis, an inflammatory skin disease. Formulated in a waterbased Hydrogel vehicle, it is indicated for patients as young as 3 months. NeoBenz® Micro is a benzoyl peroxide medication for the treatment of mild to moderate acne vulgaris. Its special formulation allows for a gradual release of the active ingredient which allows for an effective treatment with only low irritation.
"We are pleased that this agreement with Intendis will allow us to devote investments to continued growth of our remaining dermatology business," said Mary Fisher, President and CEO of SkinMedica. "We look forward to expanding our pipeline of innovative products for the improvement of skin appearance and the treatment of dermatologic conditions."
About Intendis
Intendis is an integrated pharmaceutical company based in Berlin, Germany.
As part of Bayer HealthCare, Intendis is completely dedicated to
Dermatology and focuses on the development, manufacturing and marketing of
high quality, innovative topical therapies, targeted to treat skin
disorders. The current product portfolio comprises treatments of eczema
disorders including atopic dermatitis, as well as psoriasis, acne, rosacea,
hemorrhoids and fungal skin infections (mycoses). Find out more at
http://www.intendis.com.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a
subsidiary of Bayer AG, is one of the world's leading, innovative companies
in the healthcare and medical products industry and is based in Leverkusen,
Germany. The company combines the global activities of the Animal Health,
Bayer Schering Pharma, Consumer Care and Medical Care divisions. Bayer
HealthCare's aim is to discover and manufacture products that will improve
human and animal health worldwide. Find more information at
http://www.bayerhealthcare.com.
About SkinMedica
SkinMedica, Inc. is focused on developing, acquiring and commercializing
products that treat dermatologic conditions and improve the appearance of
skin. SkinMedica markets and sells, primarily to dermatologists, both
prescription pharmaceutical products and physician-dispensed,
non-prescription skin care products. SkinMedica is based in Carlsbad,
California. For more information, visit: http://www.skinmedica.com.
Desonate®, EpiQuin® Micro, NeoBenz® Micro, SkinMedica®, TNS Recovery Complex® and VANIQA® are registered trademarks of SkinMedica, Inc and affiliates.